Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

COVID-19 antibodies on trial
Laura DeFrancesco
Nature Biotechnology (2020) Vol. 38, Iss. 11, pp. 1242-1252
Open Access | Times Cited: 119

Showing 1-25 of 119 citing articles:

The antigenic anatomy of SARS-CoV-2 receptor binding domain
Wanwisa Dejnirattisai, Daming Zhou, Helen M. Ginn, et al.
Cell (2021) Vol. 184, Iss. 8, pp. 2183-2200.e22
Open Access | Times Cited: 390
Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6–8 months after the infection
Natalia Sherina, Antonio Piralla, Likun Du, et al.
Med (2021) Vol. 2, Iss. 3, pp. 281-295.e4
Open Access | Times Cited: 192
Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants
Zhiqiang Ku, Xuping Xie, Paul R. Hinton, et al.
Nature (2021) Vol. 595, Iss. 7869, pp. 718-723
Open Access | Times Cited: 158
Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses
Sham Nambulli, Yufei Xiang, Natasha L. Tilston‐Lunel, et al.
Science Advances (2021) Vol. 7, Iss. 22
Open Access | Times Cited: 140
Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice
Raoul De Gasparo, Mattia Pedotti, Luca Simonelli, et al.
Nature (2021) Vol. 593, Iss. 7859, pp. 424-428
Open Access | Times Cited: 129
An update to monoclonal antibody as therapeutic option against COVID-19
Paroma Deb, Md. Maruf Ahmed Molla, KM Saif‐Ur‐Rahman
Biosafety and Health (2021) Vol. 3, Iss. 2, pp. 87-91
Open Access | Times Cited: 118
Neutralizing Antibody Therapeutics for COVID-19
Aeron C. Hurt, Adam K. Wheatley
Viruses (2021) Vol. 13, Iss. 4, pp. 628-628
Open Access | Times Cited: 118
Current Strategies of Antiviral Drug Discovery for COVID-19
Miao Mei, Xu Tan
Frontiers in Molecular Biosciences (2021) Vol. 8
Open Access | Times Cited: 95
Neutralization of SARS‐CoV‐2 by highly potent, hyperthermostable, and mutation‐tolerant nanobodies
Thomas Güttler, Metin Aksu, Antje Dickmanns, et al.
The EMBO Journal (2021) Vol. 40, Iss. 19
Open Access | Times Cited: 89
A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19
Vibeke Backer, Ulf Sjöbring, Jesper Sonne, et al.
The Lancet Regional Health - Europe (2021) Vol. 4, pp. 100084-100084
Open Access | Times Cited: 61
Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection
Lei Li, Yoshikazu Honda‐Okubo, Ying Huang, et al.
Vaccine (2021) Vol. 39, Iss. 40, pp. 5940-5953
Open Access | Times Cited: 61
Intranasal influenza-vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory response in hamsters
Liang Zhang, Yao Jiang, Jinhang He, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 30
Nasal sprays for treating COVID-19: a scientific note
Vivek P. Chavda, Kajal Baviskar, Dixa A. Vaghela, et al.
Pharmacological Reports (2023) Vol. 75, Iss. 2, pp. 249-265
Open Access | Times Cited: 26
Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents
Joshua Wolf, Mark J. Abzug, Rachel L Wattier, et al.
Journal of the Pediatric Infectious Diseases Society (2020) Vol. 10, Iss. 5, pp. 629-634
Open Access | Times Cited: 58
Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies
Erik Laurini, Domenico Marson, Suzana Aulić, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 51
Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment
Norma A. Valdez‐Cruz, Enrique García‐Hernández, Clara Espitia, et al.
Microbial Cell Factories (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 48
Receptor binding, immune escape, and protein stability direct the natural selection of SARS-CoV-2 variants
Vaibhav Upadhyay, Alexandra Lucas, Sudipta Panja, et al.
Journal of Biological Chemistry (2021) Vol. 297, Iss. 4, pp. 101208-101208
Open Access | Times Cited: 47
Denaturing and Native Mass Spectrometric Analytics for Biotherapeutic Drug Discovery Research: Historical, Current, and Future Personal Perspectives
Iain D. G. Campuzano, Wendy Sandoval
Journal of the American Society for Mass Spectrometry (2021) Vol. 32, Iss. 8, pp. 1861-1885
Closed Access | Times Cited: 41
Cost and supply considerations for antibody therapeutics
Chun Chen, Z. García, David Chen, et al.
mAbs (2025) Vol. 17, Iss. 1
Open Access
Prospects of Neutralizing Nanobodies Against SARS-CoV-2
Fangfang Chen, Zhihong Liu, Fan Jiang
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 36
A super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection
Ami Miller, Adam Leach, Jemima C. Thomas, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 32
Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants
Jia Lu, Qiangling Yin, Rongjuan Pei, et al.
Virologica Sinica (2022) Vol. 37, Iss. 2, pp. 238-247
Open Access | Times Cited: 24
Neutralizing antibody: a savior in the Covid-19 disease
Sneh Lata Gupta, Rishi Kumar Jaiswal
Molecular Biology Reports (2022) Vol. 49, Iss. 3, pp. 2465-2474
Open Access | Times Cited: 23
Potent TRIM21 and complement-dependent intracellular antiviral immunity requires the IgG3 hinge
Stian Foss, Alexandra Jonsson, Maria Bottermann, et al.
Science Immunology (2022) Vol. 7, Iss. 70
Open Access | Times Cited: 23
Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?
Jingjing Zhang, Han Zhang, Litao Sun
mAbs (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top